Jab1 and EGFR Signaling in Breast Cancer
Author Information
Author(s): Wang Jiaxu, Barnes Rebecca O, West Nathan R, Olson Melanie, Chu Jenny E, Watson Peter H
Primary Institution: BC Cancer Agency
Hypothesis
Jab1 mediates EGFR signaling in ERα-negative breast cancer.
Conclusion
Jab1 is a target of EGFR signaling in ERα- cell lines and breast tumors, suggesting it may be a potential therapeutic target.
Supporting Evidence
- EGF treatment increased Jab1 nuclear expression in breast cancer cell lines.
- High Jab1 expression was associated with EGFR and S100A7 in ERα- tumors.
- Jab1 knockdown restored p27 levels in EGF-treated cells.
Takeaway
Jab1 helps EGFR work in breast cancer cells that don't have estrogen receptors, which could help doctors find new treatments.
Methodology
Cell lines were treated with EGF and analyzed for Jab1 localization and expression in a cohort of breast tumors using immunohistochemistry.
Limitations
The study did not find strong correlations between Jab1 expression and standard prognostic features.
Participant Demographics
Cohort included 424 invasive breast carcinomas with various clinical-pathological features.
Statistical Information
P-Value
0.019
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website